{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:15:34Z","timestamp":1791123334532,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,16]],"date-time":"2014-04-16T00:00:00Z","timestamp":1397606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.cjca.2013.12.001","type":"journal-article","created":{"date-parts":[[2013,12,5]],"date-time":"2013-12-05T04:15:41Z","timestamp":1386216941000},"page":"S9-S15","source":"Crossref","is-referenced-by-count":69,"special_numbering":"S","title":["Contemporary Use of \u03b2-Blockers: Clinical Relevance of Subclassification"],"prefix":"10.1016","volume":"30","author":[{"given":"Luc","family":"Poirier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheldon W.","family":"Tobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2013.12.001_bib1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cjca.2012.10.007","article-title":"The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure","volume":"29","author":"McKelvie","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2013.12.001_bib2","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"O'Gara","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.12.001_bib3","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.cjca.2013.01.005","article-title":"The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension","volume":"29","author":"Hackam","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2013.12.001_bib4","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","article-title":"Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis","volume":"366","author":"Lindholm","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2013.12.001_bib5","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.279.23.1903","article-title":"Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review","volume":"279","author":"Messerli","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2013.12.001_bib6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.5694\/j.1326-5377.2004.tb06178.x","article-title":"Barriers to diagnosing and managing heart failure in primary care","volume":"181","author":"Phillips","year":"2004","journal-title":"Med J Aust"},{"key":"10.1016\/j.cjca.2013.12.001_bib7","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1345\/aph.1C472","article-title":"Beta-blocker underuse in secondary prevention of myocardial infarction","volume":"38","author":"Everly","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cjca.2013.12.001_bib8","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0195-668X(02)00700-5","article-title":"The EuroHeart Failure Survey programme\u2013a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment","volume":"24","author":"Komajda","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2013.12.001_bib9","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1525-1497.2003.20414.x","article-title":"Misperceptions about beta-blockers and diuretics: a national survey of primary care physicians","volume":"18","author":"Ubel","year":"2003","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.cjca.2013.12.001_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1472-8206.2009.00757.x","article-title":"The challenge of polypharmacy in cardiovascular medicine","volume":"24","author":"Volpe","year":"2010","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.cjca.2013.12.001_bib11","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1097\/01.hjh.0000249685.58370.28","article-title":"How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis","volume":"24","author":"Bradley","year":"2006","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.cjca.2013.12.001_bib12","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cjca.2012.04.001","article-title":"The evolving role of \u03b2-adrenergic receptor blockers in managing hypertension","volume":"28","author":"Poirier","year":"2012","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2013.12.001_bib13","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1056\/NEJM199508103330612","article-title":"The beta 3-adrenergic receptor\u2013a cause and cure of obesity?","volume":"333","author":"Arner","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2013.12.001_bib14","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1212\/WNL.0b013e31822b007a","article-title":"Effects of \u03b2-blocker selectivity on blood pressure variability and stroke: a systematic review","volume":"77","author":"Webb","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.cjca.2013.12.001_bib15","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1152\/ajplegacy.1948.153.3.586","article-title":"A\u00a0study of the adrenergic receptors","volume":"153","author":"Ahlquist","year":"1948","journal-title":"Am J Physiol"},{"key":"10.1016\/j.cjca.2013.12.001_bib16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.tips.2011.02.001","article-title":"The major impacts of James Black's drug discoveries on medicine and pharmacology","volume":"32","author":"Walker","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.cjca.2013.12.001_bib17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1751-7176.2009.00140.x","article-title":"Realities of newer Beta-blockers for the management of hypertension","volume":"11","author":"Manrique","year":"2009","journal-title":"J\u00a0Clin Hypertens"},{"key":"10.1016\/j.cjca.2013.12.001_bib18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1751-7176.2011.00515.x","article-title":"Beta-Adrenergic blockers","volume":"13","author":"Frishman","year":"2011","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.cjca.2013.12.001_bib19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/FJC.0b013e3181ad207b","article-title":"Evolving mechanisms of action of beta blockers: focus on nebivolol","volume":"54","author":"Mason","year":"2009","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2013.12.001_bib20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11883-010-0157-9","article-title":"The role of beta-blockers as first-line therapy in hypertension","volume":"13","author":"De Caterina","year":"2011","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.cjca.2013.12.001_bib21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.coph.2012.12.002","article-title":"Beta blockers, nitric oxide, and cardiovascular disease","volume":"13","author":"Vanhoutte","year":"2013","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.cjca.2013.12.001_bib22","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0140-6736(00)03307-9","article-title":"Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration","volume":"356","author":"Neal","year":"2000","journal-title":"Lancet"},{"issue":"5\u00a0suppl","key":"10.1016\/j.cjca.2013.12.001_bib23","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.cjca.2014.01.006","article-title":"Atenolol vs nonatenolol \u03b2-blockers for the treatment of hypertension: a meta-analysis","volume":"30","author":"Kuyper","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2013.12.001_bib24","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1503\/cmaj.060110","article-title":"Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis","volume":"174","author":"Khan","year":"2006","journal-title":"CMAJ"},{"key":"10.1016\/j.cjca.2013.12.001_bib25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S0002-9149(03)00645-3","article-title":"Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension","volume":"92","author":"Kamp","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2013.12.001_bib26","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.amjcard.2009.12.068","article-title":"Why beta-blockers should not be used as first choice in uncomplicated hypertension","volume":"105","author":"De Caterina","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2013.12.001_bib27","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jama.2012.12559","article-title":"\u03b2-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease","volume":"308","author":"Bangalore","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2013.12.001_bib28","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0002-9149(00)01520-4","article-title":"Comparative effects of three beta blockers (atenolol, metoprolol, and propranolol) on survival after acute myocardial infarction","volume":"87","author":"Gottlieb","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2013.12.001_bib29","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.1982.03320370021023","article-title":"Beta-Blocker Heart Attack Trial Research Group. A\u00a0randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results","volume":"247","year":"1982","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2013.12.001_bib30","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial","volume":"357","author":"Dargie","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2013.12.001_bib31","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1136\/bmj.318.7200.1730","article-title":"Beta blockade after myocardial infarction: systematic review and meta regression analysis","volume":"318","author":"Freemantle","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2013.12.001_bib32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2013.12.001_bib33","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group","volume":"334","author":"Packer","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2013.12.001_bib34","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"MERIT-HF Study Group. Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2013.12.001_bib35","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11906-006-0065-0","article-title":"The latest generation of beta-blockers: new pharmacologic properties","volume":"8","author":"Pedersen","year":"2006","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.cjca.2013.12.001_bib36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2013.12.001_bib37","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.jacc.2013.01.020","article-title":"Effect of metoprolol versus carvedilol on outcomes in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy)","volume":"61","author":"Ruwald","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.12.001_bib38","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.cjca.2011.07.004","article-title":"Bucindolol, systolic blood pressure, and outcomes in systolic heart failure: a prespecified post hoc analysis of BEST","volume":"28","author":"White","year":"2012","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2013.12.001_bib39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2013.12.001_bib40","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijcard.2007.01.069","article-title":"Are we misunderstanding beta-blockers","volume":"120","author":"Cruickshank","year":"2007","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2013.12.001_bib41","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1038\/sj.bjp.0704188","article-title":"Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium","volume":"133","author":"Brixius","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cjca.2013.12.001_bib42","doi-asserted-by":"crossref","first-page":"169S","DOI":"10.1016\/j.amjhyper.2005.09.009","article-title":"The role of the new beta-blockers in treating cardiovascular disease","volume":"18","author":"Weber","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2013.12.001_bib43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0002-9343(93)90181-N","article-title":"Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents","volume":"94","author":"Neutel","year":"1993","journal-title":"Am J Med"},{"key":"10.1016\/j.cjca.2013.12.001_bib44","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2013.12.001_bib45","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1161\/CIRCULATIONAHA.105.595496","article-title":"Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study","volume":"113","author":"Williams","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.12.001_bib46","first-page":"CD002003","article-title":"Beta-blockers for hypertension (Review)","author":"Wiysonge","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cjca.2013.12.001_bib47","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/HJH.0b013e32835e8f5b","article-title":"A\u00a0prospective, randomized, open-label, active-controlled, clinical trial to assess central haemodynamic effects of bisoprolol and atenolol in hypertensive patients","volume":"31","author":"Park","year":"2013","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.cjca.2013.12.001_bib48","doi-asserted-by":"crossref","first-page":"165S","DOI":"10.1016\/j.amjhyper.2005.09.010","article-title":"The role of beta-blockers as a cornerstone of cardiovascular therapy","volume":"18","author":"Hollenberg","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2013.12.001_bib49","first-page":"CD003566","article-title":"Cardioselective beta-blockers for chronic obstructive pulmonary disease","author":"Salpeter","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cjca.2013.12.001_bib50","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.amjhyper.2005.11.011","article-title":"Carvedilol action is dependent on endogenous production of nitric oxide","volume":"19","author":"Afonso","year":"2006","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2013.12.001_bib51","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/ajh.2008.260","article-title":"Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients","volume":"21","author":"Pasini","year":"2008","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2013.12.001_bib52","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/FJC.0b013e31819fd501","article-title":"An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade","volume":"53","author":"Bakris","year":"2009","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2013.12.001_bib53","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.amjhyper.2004.05.023","article-title":"Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment","volume":"17","author":"Schiffrin","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2013.12.001_bib54","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ajh.2008.156","article-title":"Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection","volume":"21","author":"Mahmud","year":"2008","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2013.12.001_bib55","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/HJH.0b013e3282f283c9","article-title":"A\u00a0comparison of atenolol and nebivolol in isolated systolic hypertension","volume":"26","author":"Dhakam","year":"2008","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.cjca.2013.12.001_bib56","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/HYPERTENSIONAHA.113.01318","article-title":"Aortic stiffness determines diastolic blood flow reversal in the descending thoracic aorta: potential implication for retrograde embolic stroke in hypertension","volume":"62","author":"Hashimoto","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2013.12.001_bib57","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1365-2796.2009.02140.x","article-title":"Cardioprotection with beta-blockers: myths, facts and Pascal's wager","volume":"266","author":"Messerli","year":"2009","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.cjca.2013.12.001_bib58","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.amjcard.2007.05.057","article-title":"A\u00a0meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus","volume":"100","author":"Bangalore","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2013.12.001_bib59","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1097\/00004872-200108000-00011","article-title":"Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients","volume":"19","author":"Poirier","year":"2001","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.cjca.2013.12.001_bib60","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1464-5491.2007.02151.x","article-title":"Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI","volume":"24","author":"Fonseca","year":"2007","journal-title":"Diabet Med"},{"key":"10.1016\/j.cjca.2013.12.001_bib61","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.amjhyper.2007.01.019","article-title":"Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus","volume":"20","author":"Bank","year":"2007","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2013.12.001_bib62","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.amjhyper.2005.03.733","article-title":"Quality of life and antihypertensive effect with nebivolol and losartan","volume":"18","author":"Vanbortel","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2013.12.001_bib63","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/08038020310023271","article-title":"Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial","volume":"2","author":"Grassi","year":"2003","journal-title":"Blood Press Suppl"},{"key":"10.1016\/j.cjca.2013.12.001_bib64","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1440-1681.2007.04551.x","article-title":"Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men","volume":"34","author":"Brixius","year":"2007","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.cjca.2013.12.001_bib65","doi-asserted-by":"crossref","first-page":"13F","DOI":"10.1016\/0002-9149(87)90035-X","article-title":"Pharmacologic aspects of intrinsic sympathomimetic activity\u00a0in beta-blocking drugs","volume":"59","author":"Prichard","year":"1987","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2013.12.001_bib66","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0002-9149(96)00820-X","article-title":"Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction. The APSI Investigators. Acebutolol et Pr\u00e9vention Secondaire de l'Infarctus","volume":"79","author":"Cucherat","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2013.12.001_bib67","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2146\/ajhp070459","article-title":"Nebivolol: a new antihypertensive agent","volume":"65","author":"Gray","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.cjca.2013.12.001_bib68","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s11906-008-0061-7","article-title":"Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapy","volume":"10","author":"Sica","year":"2008","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.cjca.2013.12.001_bib69","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2165\/11591680-000000000-00000","article-title":"Is antiarrhythmic treatment in the elderly different? A review of the specific changes","volume":"28","author":"Deneer","year":"2011","journal-title":"Drugs Aging"},{"key":"10.1016\/j.cjca.2013.12.001_bib70","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(95)90694-0","article-title":"Cardiac vagal activity: a target for intervention in heart disease","volume":"345","author":"Townend","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2013.12.001_bib71","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.288.3.351","article-title":"Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction","volume":"288","author":"Ko","year":"2002","journal-title":"JAMA"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X1301708X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X1301708X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T11:25:49Z","timestamp":1597145149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X1301708X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0828282X1301708X"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2013.12.001","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}